MedPath

Drug Toxicity Leads to Early Discontinuation of Niraparib in Ovarian Cancer Treatment

A recent study highlights drug toxicity as the primary reason for early discontinuation of niraparib, a PARP inhibitor, in patients with epithelial ovarian cancer. The CHAR1ZMA study underscores the importance of individualized starting doses and dose modifications to manage toxicity effectively, aiming to prolong treatment duration and maximize therapeutic benefits.

Drug Toxicity and Early Discontinuation of Niraparib in Ovarian Cancer

Drug toxicity has been identified as the most common reason for the early discontinuation of first-line maintenance monotherapy with niraparib (Zejula) among patients with epithelial ovarian cancer, according to findings from the real-world CHAR1ZMA study. This research, published in the International Journal of Gynecological Cancer, emphasizes the critical need for healthcare providers to focus on effective toxicity management, particularly during the initial 90 days of treatment, and to consider individualized starting doses based on patient-specific factors.

Study Overview

The CHAR1ZMA study analyzed electronic health records of 560 adult patients with epithelial ovarian cancer who received niraparib as a first-line monotherapy. The study period spanned from January 2017 to December 2022, with patients diagnosed no earlier than January 2015. Among the participants, 161 discontinued treatment early, while 399 did not.

Key Findings

  • Toxicity as a Primary Cause: 67.7% of early discontinuers cited toxicity as the reason, compared to 18.1% in those who did not discontinue early.
  • Dose Modifications: Early discontinuers were less likely to undergo dose modifications (29.8% vs. 53.6% in non-early discontinuers).
  • Disease Progression: In contrast, disease progression was the most common reason for discontinuation among non-early discontinuers (74.8% vs. 30.4% in early discontinuers).
  • Treatment Duration: The median treatment duration was 7.2 months overall, with a significant difference between early discontinuers and those who continued treatment (4.5 months longer in the latter group).

Importance of Individualized Starting Doses

The study also highlighted the role of individualized starting doses (ISDs) based on body weight and platelet count. A majority of patients (58.8%) received niraparib at their ISD, with variations in dosage affecting treatment outcomes. Early discontinuers were more likely to receive doses higher than their ISD, suggesting a missed opportunity for appropriate dose modifications.

Conclusion

Researchers advocate for enhanced education among healthcare providers on the importance of early clinical management of toxicity, including the use of ISDs and timely dose modifications. Such strategies could enable patients to remain on first-line maintenance niraparib treatment longer, thereby experiencing the full therapeutic benefits.
Reference: Backes FJ, Boyle TAC, Lim J, et al. Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA study. Int J Gynecol Cancer. 2024;0(0):1-9. doi: doi.org/10.1016/j.ijgc.2024.100044
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

ZEST Trial Halted Due to Low ctDNA Detection Rates in Early Breast Cancer

The Phase III ZEST trial, evaluating niraparib for preventing breast cancer recurrence based on circulating tumor DNA (ctDNA), was terminated early due to low ctDNA detection rates.
Broad entry criteria in ZEST led to the inclusion of low-risk patients, resulting in a low rate of ctDNA positivity and hindering the trial's randomization process.

Weight Loss Jabs Like Ozempic May Reduce Effectiveness of Breast Cancer Treatments, Study Finds

A recent study suggests that weight loss injections, including Ozempic and Wegovy, could render chemotherapy and immunotherapy less effective for breast cancer patients, particularly those with triple negative breast cancer. The research indicates that patients on these drugs were less likely to be cancer-free after treatment, raising concerns about their use during cancer therapy.

Niraparib Maintenance Shows Sustained Progression-Free Survival Benefit in Advanced Ovarian Cancer, But No Overall Survival Improvement

Final analysis of the PRIMA trial showed niraparib maintenance did not improve overall survival in advanced ovarian cancer patients after platinum-based chemotherapy.
Niraparib demonstrated a sustained progression-free survival benefit, with a 22% rate at 5 years compared to 12% with placebo in the overall population.

Niraparib Shows Promise in Extending Progression-Free Survival in Epithelial Ovarian Cancer

Niraparib monotherapy extends real-world progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC).
Patients with homologous recombination-deficient (HRd) tumors, particularly those with BRCA-mutated tumors, experienced longer rwPFS and rwTTNT.

Atezolizumab Fails to Improve Progression-Free Survival in Recurrent Ovarian Cancer

A phase III trial (ENGOT-OV41/GEICO 69-O/ANITA) assessed atezolizumab with platinum-based chemotherapy and niraparib maintenance in recurrent ovarian cancer patients.
The addition of atezolizumab did not significantly improve progression-free survival compared to placebo in patients with platinum-free interval > 6 months.

Olaparib/Cediranib Combination Fails to Improve Survival in Relapsed Ovarian Cancer

The phase 3 ICON9 trial investigated olaparib plus cediranib versus olaparib alone as maintenance therapy for relapsed platinum-sensitive ovarian cancer.
The combination of olaparib and cediranib did not significantly improve progression-free survival compared to olaparib monotherapy (HR = 0.84; 95% CI, 0.65-1.07; P = .24).

Comparative Analysis of PARP Inhibitors in BRCA-Mutated Ovarian Cancer Shows Similar Efficacy and Toxicity

A network meta-analysis of PARP inhibitors (PARPi) in BRCA-mutated ovarian cancer reveals no significant differences in efficacy among various regimens used in upfront or relapsed settings.
The study assesses the cost-effectiveness of PARPi regimens using the ASCO value framework, indicating similar clinical benefits, toxicity, and net health benefit across different treatments.

PARP Inhibitors Show Similar Efficacy in BRCA-Mutated Ovarian Cancer, Cost-Effectiveness Varies

A network meta-analysis reveals no significant differences in efficacy among PARP inhibitor regimens for BRCA-mutated ovarian cancer patients in upfront or relapsed settings.
The ASCO value framework suggests similar clinical benefits and toxicity profiles across PARP inhibitor regimens in both upfront and relapsed settings.

PARP Inhibitors in Frontline Ovarian Cancer Treatment: A Review of Clinical Trials

Frontline PARP inhibitor maintenance shows greatest benefit in patients with BRCA-associated ovarian cancers, followed by those with homologous recombination deficient (HRD) tumors.
Key factors in deciding on frontline PARP inhibitor therapy include FDA indication, dosing preference, toxicity profiles, patient-specific risk-benefit assessment, and cost considerations.

Niraparib Maintenance Therapy Demonstrates Sustained Benefit in Recurrent Ovarian Cancer

Niraparib maintenance therapy significantly improves progression-free survival (PFS) in patients with recurrent, platinum-sensitive ovarian cancer, regardless of BRCA mutation status.
The NOVA trial, a phase 3 study, demonstrated a statistically significant and clinically meaningful benefit with niraparib compared to placebo in prolonging time to disease progression.

Reference News

[1]
Drug Toxicity May Drive Early Niraparib Discontinuation in Ovarian Cancer - Oncology Nursing News
oncnursingnews.com · Jan 16, 2025

Drug toxicity was the primary reason for early discontinuation of niraparib in epithelial ovarian cancer patients, per t...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy